Armata Pharmaceuticals In... (ARMP)
Armata Pharmaceuticals Statistics
Share Statistics
Armata Pharmaceuticals has 36.18M shares outstanding. The number of shares has increased by 0.08% in one year.
| Shares Outstanding | 36.18M |
| Shares Change (YoY) | 0.08% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 3.84% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,313 |
| FTD / Avg. Volume | 7.98% |
Short Selling Information
The latest short interest is 6.25K, so 0.02% of the outstanding shares have been sold short.
| Short Interest | 6.25K |
| Short % of Shares Out | 0.02% |
| Short % of Float | 0.06% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -3.54 and the forward PE ratio is -2.17. Armata Pharmaceuticals's PEG ratio is 0.05.
| PE Ratio | -3.54 |
| Forward PE | -2.17 |
| PS Ratio | 0 |
| Forward PS | 0.8 |
| PB Ratio | -1.39 |
| P/FCF Ratio | -1.7 |
| PEG Ratio | 0.05 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Armata Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.23, with a Debt / Equity ratio of -2.63.
| Current Ratio | 0.23 |
| Quick Ratio | 0.23 |
| Debt / Equity | -2.63 |
| Debt / EBITDA | -2.98 |
| Debt / FCF | -3.21 |
| Interest Coverage | 3.95 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-315,266.67 |
| Employee Count | 60 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -48.19% in the last 52 weeks. The beta is 0.92, so Armata Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.92 |
| 52-Week Price Change | -48.19% |
| 50-Day Moving Average | 1.64 |
| 200-Day Moving Average | 2.14 |
| Relative Strength Index (RSI) | 46.56 |
| Average Volume (20 Days) | 16,462 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -42.44M |
| Net Income | -18.92M |
| EBITDA | -42.44M |
| EBIT | -29.66M |
| Earnings Per Share (EPS) | -0.52 |
Balance Sheet
The company has 9.29M in cash and 126.52M in debt, giving a net cash position of -117.22M.
| Cash & Cash Equivalents | 9.29M |
| Total Debt | 126.52M |
| Net Cash | -117.22M |
| Retained Earnings | -327.74M |
| Total Assets | 86.44M |
| Working Capital | -36.94M |
Cash Flow
In the last 12 months, operating cash flow was -37.55M and capital expenditures -1.88M, giving a free cash flow of -39.43M.
| Operating Cash Flow | -37.55M |
| Capital Expenditures | -1.88M |
| Free Cash Flow | -39.43M |
| FCF Per Share | -1.09 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ARMP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for ARMP is $7, which is 442.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $7 |
| Price Target Difference | 442.6% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on May 10, 2019. It was a backward split with a ratio of 1:14.
| Last Split Date | May 10, 2019 |
| Split Type | backward |
| Split Ratio | 1:14 |
Scores
| Altman Z-Score | -5.89 |
| Piotroski F-Score | 1 |